Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Views 116
Citations 0
Capitol Health Call
October 10, 2012

New HIV Drug Pricing

JAMA. 2012;308(14):1421. doi:10.1001/jama.2012.13452

Gilead Sciences set an annual wholesale price of $28 500 for its once-daily single-tablet HIV-1 medication following its August 27 approval by the Food and Drug Administration. The decision might disappoint 13 Democratic representatives who had asked the company to set a more affordable price. The tablet contains a combination of 4 drugs: cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate.

In an August 1 letter to Gilead Sciences, the representatives said setting a wholesale price above $27 000 annually for the tablet would cause problems for the AIDS Drug Assistance Program (ADAP), the federally funded program that helps states purchase HIV/AIDS drugs for low-income individuals who have limited or no prescription drug coverage. ADAP is funded through the Ryan White Program.

First Page Preview View Large
First page PDF preview
First page PDF preview